Paper Details
- Home
- Paper Details
The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
Author: AttiaD, AyoubH, El SheemyR Y, El-KhayatH R, El-SayedM H, El-ShabrawiM, FouadY M, KamalE M, MaherM, RizKA
Original Abstract of the Article :
BACKGROUND: The combination of ledipasvir plus sofosbuvir was recently approved for treatment of adolescent (12-17 years) HCV genotype 1, 4, 5 & 6 patients. However, few clinical trials have been performed in genotype 1 patients. AIM: To investigate the effectiveness and safety of ledipasvir plus s...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1111/apt.14502
データ提供：米国国立医学図書館（NLM）
A New Era in Hepatitis C Treatment
This research takes us on a journey through the intricate world of [chronic hepatitis C virus (HCV) infection], a serious liver disease. The authors focus on the effectiveness and safety of ledipasvir plus sofosbuvir, a powerful combination therapy for treating HCV genotype 4 in adolescents. The study involved 144 adolescents with HCV genotype 4, all of whom received ledipasvir plus sofosbuvir for 12 weeks. The results revealed a remarkably high sustained virological response (SVR12) rate, suggesting that this combination therapy is highly effective in eradicating HCV in adolescents. The study also found that ledipasvir plus sofosbuvir was well-tolerated, with minimal side effects. This research, like a beacon of hope in the desert of HCV treatment, offers a promising avenue for combating this challenging condition.Ledipasvir Plus Sofosbuvir: A Powerful Weapon
This research highlights the remarkable efficacy of ledipasvir plus sofosbuvir in treating chronic hepatitis C virus (HCV) genotype 4 in adolescents. The study's findings suggest that this combination therapy can effectively eliminate HCV, offering a potential for long-term cure. This research, like a well in the desert, provides a valuable resource for managing this serious liver disease.Hope for a Hepatitis C-Free Future
This research offers a glimmer of hope for adolescents facing the challenge of chronic hepatitis C virus (HCV) infection. The study's findings suggest that ledipasvir plus sofosbuvir could be a game-changer in the fight against HCV, offering a potential for long-term cure and improving the lives of those affected.Dr.Camel's Conclusion
This research highlights the effectiveness and safety of ledipasvir plus sofosbuvir in treating chronic hepatitis C virus (HCV) genotype 4 in adolescents. The study's findings suggest that this combination therapy offers a promising avenue for combating HCV, potentially leading to a cure for this debilitating liver disease. This research, like a journey through the desert, reminds us of the continuous search for new and effective treatments for challenging conditions.Date :
- Date Completed 2019-06-12
- Date Revised 2022-03-17
Further Info :
Related Literature
Article Analysis
SNS
PICO Info
in preparation
Languages
English
Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.